NASDAQ$NVCT
Nuvectis Pharma Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2024 and provided an update on recent business progress.
Nuvectis Pharma reported a net loss of $4.2 million for Q1 2024, compared to $4.0 million for Q1 2023. The company's cash and cash equivalents increased slightly to $19.5 million. Clinical development programs for NXP800 and NXP900 continued to advance.
- NXP800 showed encouraging preliminary data in a Phase 1b study for platinum-resistant, ARID1a-mutated ovarian cancer.
- Patient enrollment in the NXP800 study has increased as more clinical sites are activated.
- NXP900's Phase 1a dose-escalation study is progressing as planned.
- New preclinical data presented at AACR 2024 confirmed NXP900's potential to re-sensitize resistant non-small cell lung cancer (NSCLC) cells to osimertinib.
Headline financials
Revenue & EPS history
Nuvectis Pharma · Revenue · Quarterly
$0
Forward guidance
2024 is shaping up to be a potentially transformational year for Nuvectis with several clinical data updates expected in the second half of the year. The company believes it has cash runway into 2H 2025.
Tailwinds
- Potential for NXP800 in platinum-resistant, ARID1a-mutated ovarian cancer.
- Advancing collaboration with Mayo Clinic for NXP800 in cholangiocarcinoma.
- NXP900 shows potential synergy with EGFR and ALK inhibitors in NSCLC cells.
- Clinical data updates expected in the second half of the year.
- Cash runway into 2H 2025.
Headwinds
- Uncertainties related to clinical trial outcomes.
- Risks associated with drug development and regulatory approvals.
- Dependence on successful collaborations.
- Potential for increased competition in the oncology space.
- Uncertainties related to market conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+2.4%
Avg return
Earnings day
+7.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
65%
13 / 20 earnings
Positive
+29.2%
Q3 2024
Best reaction
-14.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.4% | +31.6% | +8.8% | |
| Q4 2026 | +0.5% | +0.2% | +3.3% | |
| Q3 2025 | -7.9% | -3.5% | +6.1% | |
| Q2 2025 | -5.4% | -17.7% | -10.6% | |
| Q1 2025 | +6.4% | +8.3% | -9.4% | |
| Q4 2024 | -5.8% | -9.1% | +31.1% | |
| Q3 2024 | +29.2% | +71.3% | -24.6% | |
| Q1 2024 | -14.9% | -15.3% | -13.6% | |
| Q4 2023 | -4.5% | -0.4% | -25.1% | |
| Q3 2023 | -7.9% | -6.6% | -8.4% | |
| Q2 2023 | +1.4% | +1.1% | -7.0% | |
| Q1 2023 | +5.8% | +6.3% | +14.0% | |
| Q4 2022 | -7.1% | -9.5% | +9.2% | |
| Q3 2021 | +0.9% | -3.5% | +7.7% | |
| Q3 2022 | +0.9% | -3.5% | +7.7% | |
| Q2 2021 | +1.1% | +10.1% | -0.6% | |
| Q2 2022 | +2.6% | -3.0% | -3.7% | |
| Q1 2021 | +18.8% | +28.8% | -24.4% | |
| Q4 2021 | +18.8% | +33.6% | -15.6% | |
| Q1 2022 | +5.4% | +25.2% | -19.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro